Repression of Vascular Endothelial Growth Factor A in Glioblastoma Cells Using Engineered Zinc Finger Transcription Factors

Cancer Research

Volumn 63, Issue 24, 2003, Pages 8968-8976

  Snowden, Andrew W ^a   Zhang, Lei ^a   Urnov, Fyodor ^a   Dent, Carolyn ^a   Jouvenot, Yann ^a   Zhong, Xiaohong ^a   Rebar, Edward J ^a   Jamieson, Andrew C ^a   Zhang, H Steven ^a   Tan, Siyuan ^a   Case, Casey C ^a   Pabo, Carl O ^a,b   Wolffe, Alan P ^a   Gregory, Philip D ^a  

^a SANGAMO BIOSCIENCES INC   (United States)

^b Point Richmond Tech Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; DNA BINDING PROTEIN; HISTONE H3; HISTONE H4; HYBRID PROTEIN; ONCOPROTEIN; THYROID HORMONE RECEPTOR ALPHA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A; ZINC FINGER PROTEIN;

ANGIOGENESIS; ARTICLE; BINDING SITE; BIOSYNTHESIS; CANCER CELL CULTURE; CONTROLLED STUDY; DEACETYLATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; GENETIC TRANSFECTION; GENETICS; GLIOBLASTOMA; HUMAN; HUMAN CELL; LIGAND BINDING; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ENGINEERING; TUMOR CELL LINE; VASCULARIZATION;

CELL LINE, TUMOR; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEINS V-ERBA; PROMOTER REGIONS (GENETICS); TRANSCRIPTION FACTORS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; ZINC FINGERS;

EID: 9144250992     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Hanahan, D., and Weinberg, R. A. The hallmarks of cancer. Cell, 100: 57-70, 2000.
2. Folkman, J. Tumor angiogenesis. Adv. Cancer Res., 43: 175-203, 1985.
3. Ferrara, N., Houck, K., Jakeman, L., and Leung, D. W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev., 13: 18-32, 1992.
4. Plate, K. H., and Risau, W. Angiogenesis in malignant gliomas. Glia, 15: 339-347, 1995.
5. Bruick, R. K., and McKnight, S. L. Building better vasculature. Genes Dev., 15: 2497-2502, 2001.
6. Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C. M., and Shafie, S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (Lond.), 284: 67-68, 1980.
7. Dvorak, H. F., Nagy, J. A., Dvorak, J. T.. and Dvorak, A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol., 133: 95-109, 1988.
8. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.), 362: 841-844, 1993.
9. Redner, R. L., Wang, J., and Liu, J. M. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood, 94: 417-428, 1999.
10. Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G., Otte, A. P., Rubin, M. A., and Chinnaiyan, A. M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (Lond.), 419: 624-629, 2002.
11. Liang, Y., Li, X. Y., Rebar, E. J., Li, P., Zhou, Y., Chen, B., Wolffe, A. P., and Case, C. C. Activation of vascular endothelial growth factor A transcription in tumorigenic glioblastoma cell lines by an enhancer with cell type-specific DNase I accessibility. J. Biol. Chem., 277: 20087-20094, 2002.
12. Jamieson, A. C., Miller, J. C., and Pabo, C. O. Drug discovery with engineered zinc finger proteins. Nat. Rev. Drug Discov., 2: 361-368, 2003.
13. Liu, P. Q., Rebar, E. J., Zhang, L., Liu, Q., Jamieson, A. C., Liang, Y., Qi, H., Li, P. X., Chen, B., Mendel, M. C., Zhong, X., Lee, Y. L., Eisenberg, S. P., Spratt, S. K., Case, C. C., and Wolffe, A. P. Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J. Biol. Chem., 276: 11323-11334, 2001.
14. Rebar, E. J., Huang, Y., Hickey, R., Nath, A. K., Meoli, D., Nath, S., Chen, B., Xu, L., Liang, Y., Jamieson, A. C., Zhang, L., Spratt, S. K., Case, C. C., Wolffe, A., and Giordano, F. J. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat. Med., 8: 1427-1432, 2002.
15. Snowden, A. W., Gregory, P. D., Case, C. C., and Pabo, C. O. Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo. Curr. Biol., 12: 2159-2166, 2002.
16. Urnov, F. D., Yee, J., Sachs, L., Collingwood, T. N., Bauer, A., Beug, H., Shi, Y. B., and Wolffe, A. P. Targeting of N-CoR and histone deacetylase 3 by the oncoprotein v-erbA yields a chromatin infrastructure-dependent transcriptional repression pathway. EMBO J., 19: 4074-4090, 2000.
17. Beug, H., Mullner, E. W., and Hayman, M. J. Insights into erythroid differentiation obtained from studies on avian erythroblastosis virus. Curr. Opin. Cell Biol., 6: 816-824, 1994.
18. Bauer, A., Mikulits, W., Lagger, G., Stengl, G., Brosch, G., and Beug, H. The thyroid hormone receptor functions as a ligand-operated developmental switch between proliferation and differentiation of erythroid progenitors. EMBO J., 17: 4291-4303, 1998.
19. Snowden, A. W., Anderson, L. A., Webster, G. A., and Perkins, N. D. A novel transcriptional repression domain mediates p21(WAF1/CIP1) induction of p300 transactivation. Mol. Cell. Biol., 20: 2676-2686, 2000.
20. Zhang, L., Spratt, S. K., Liu, Q., Johnstone, B., Qi, H., Raschke, E. E., Jamieson, A. C., Rebar, E. J., Wolffe, A. P., and Case, C. C. Synthetic zinc finger transcription factor action at an endogenous chromosomal site. Activation of the human erythropoietin gene. J. Biol. Chem., 275: 33850-33860, 2000.
21. Chen, J. D., Umesono, K., and Evans, R. M. SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers. Proc. Natl. Acad. Sci. USA, 93: 7567-7571, 1996.
22. Huang, E. Y., Zhang, J., Miska, E. A., Guenther, M. G., Kouzarides, T., and Lazar, M. A. Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev., 14: 45-54, 2000.
23. Li, J., Wang, J., Nawaz, Z., Liu, J. M., Qin, J., and Wong, J. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J., 19: 4342-4350, 2000.
24. Collingwood, T. N., Urnov, F. D., and Wolffe, A. P. Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J. Mol. Endocrinol., 23: 255-275, 1999.
25. Sap, J., Munoz, A., Schmitt, J., Stunnenberg, H., and Vennstrom, B. Repression of transcription mediated at a thyroid hormone response element by the v-erb-A oncogene product. Nature (Lond.), 340: 242-244, 1989.
26. Damm, K., Thompson, C. C., and Evans, R. M. Protein encoded by v-erbA functions as a thyroid-hormone receptor antagonist. Nature (Lond.), 339: 593-597, 1989.
27. Zenke, M., Munoz, A., Sap, J., Vennstrom, B., and Beug, H. v-erbA oncogene activation entails the loss of hormone-dependent regulator activity of c-erbA. Cell, 61: 1035-1049, 1990.
28. Ciana, P., Braliou, G. G., Demay, F. G., von Lindern, M., Barettino, D., Beug, H., and Stunnenberg, H. G. Leukemic transformation by the v-ErbA oncoprotein entails constitutive binding to and repression of an erythroid enhancer in vivo. EMBO J., 17: 7382-7394, 1998.
29. Guenther, M. G., Lane, W. S., Fischle, W., Verdin, E., Lazar, M. A., and Shiekhattar, R. A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev., 14: 1048-1057, 2000.
30. Wen, Y. D., Perissi, V., Staszewski, L. M., Yang, W. M., Krones, A., Glass, C. K., Rosenfeld, M. G., and Seto, E. The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc. Natl. Acad. Sci. USA, 97: 7202-7207, 2000.
31. Rietveld, L. E., Caldenhoven, E., and Stunnenberg, H. G. In vivo repression of an erythroid-specific gene by distinct corepressor complexes. EMBO J., 21: 1389-1397, 2002.
32. Rietveld, L. E., Caldenhoven, E., and Stunnenberg, H. G. Avian erythroleukemia: a model for corepressor function in cancer. Oncogene. 20: 3100-3109, 2001.
33. Cheng, S. Y., Huang, H. J., Nagane, M., Ji, X. D., Wang, D., Shih, C. C., Arap, W., Huang, C. M., and Cavenee, W. K. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA, 93: 8502-8507, 1996.
34. 165 overexpression enhances tumorigenicity in U251 MG but not in NG-1 glioma cells. Cancer Res., 62: 1854-1861, 2002.
35. 1 arrest in vitro. J. Cell. Physiol., 99: 43-54, 1979.
36. Im, S. A., Kim, J. S., Gomez-Manzano, C., Fueyo, J., Liu, T. J., Cho, M. S., Seong, C. M., Lee, S. N., Hong, Y. K., and Yung, W. K. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br. J. Cancer, 84: 1252-1257, 2001.
37. Im, S. A., Gomez-Manzano, C., Fueyo, J., Liu, T. J., Ke, L. D., Kim, J. S., Lee, H. Y., Steck, P. A., Kyritsis, A. P., and Yung, W. K. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res., 59: 895-900, 1999.
38. Zhang, L., Yang, N., Mohamed-Hadley, A., Rubin, S. C., and Coukos, G. Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem. Biophys. Res. Commun., 303: 1169-1178, 2003.
39. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., 3: 639-645, 1997.
40. Ramachandra, M., Rahman, A., Zou, A., Vaillancourt, M., Howe, J. A., Antelman, D., Sugarman, B., Demers, G. W., Engler, H., Johnson, D., and Shabram, P. Reengineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat. Biotechnol., 19: 1035-1041, 2001.
41. Tonnesen, M. G., Feng, X., and Clark, R. A. Angiogenesis in wound healing. J. Investig. Dermatol. Symp. Proc., 5: 40-46, 2000.
42. Beerli, R. R., Dreier, B., and Barbas, C. F., III. Positive and negative regulation of endogenous genes by designed transcription factors. Proc. Natl. Acad. Sci. USA, 97: 1495-1500, 2000.
43. Choo, Y., Sanchez-Garcia, I., and Klug, A. In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence. Nature (Lond.), 372: 642-645, 1994.
44. Reynolds, L., Ullman, C., Moore, M., Isalan, M., West, M. J., Clapham, P., Klug, A., and Choo, Y. Repression of the HIV-1 5′ LTR promoter and inhibition of HIV-1 replication by using engineered zinc-finger transcription factors. Proc. Natl. Acad. Sci. USA, 100: 1615-1620, 2003.
45. Papworth, M., Moore, M., Isalan, M., Minczuk, M., Choo, Y., and Klug, A. Inhibition of herpes simplex virus 1 gene expression by designer zinc-finger transcription factors. Proc. Natl. Acad. Sci. USA, 100: 1621-1626, 2003.